DR. STEVEN JOEL SHIFF, M.D.
Osteopathic Medicine in Jersey City, NJ

6201028, Mar 13, 2001

Dec 8, 1998

9/208613

Steven Shiff - New York NY
Edward A. Fisher - Scarsdale NY
I. Bernard Weinstein - Englewood NY
Hayes M. Dansky - Larchmont NY

The Rockefeller University - New York NY
Mt. Sinai School of Medicine - New York NY
Columbia University - New York NY

A01N 4340

514824

Methods and compositions for the prevention and/or treatment of cardiovascular diseases, the methods comprising administering to individuals in need thereof, an effective amount of a non-steroidal anti-inflammatory drug alone or in combination with other conventional therapies to induce apoptosis, reduce proliferation, induce quiescence, inhibit cell migration, or influence cell differentiation of the cells in the vascular wall and or/induce hypolipidemia.

6620853, Sep 16, 2003

Dec 8, 1999

09/456633

Steven Shiff - New York NY
Edward A. Fisher - Scarsdale NY
Hayes M. Dansky - Larchmont NY
Ernane Reis - New York NY

Mount Sinai School of Medicine - New York NY
The Rockefeller University - New York NY

A61K 31192

514708, 514568, 514569, 514570, 514420, 5142265, 514824

Methods and compositions for the prevention and/or treatment of vascular restenosis, the methods comprising administering to individuals in need thereof, an effective amount of a non-steroidal anti-inflammatory drug alone or in combination with other conventional therapies to induce apoptosis, reduce proliferation, induce quiescence, inhibit cell migration, or influence cell differentiation of the cells in the vascular wall and or/induce hypolipidemia.

5942396, Aug 24, 1999

Aug 19, 1997

8/914105

Steven J. Shiff - New York NY
Basil Rigas - Nashua NH

The Rockefeller University - New York NY

C12Q 168, C12Q 100, G01N 33574

435 6

Methods are described for determining in individuals with or without a prior history of colorectal neoplasia whether the individual has had, has, or has a risk of developing colorectal neoplasia. The method involves an assessment of the extent of apoptosis, or programmed cell death, in a colorectal biopsy specimen. Any of numerous methods to measure the extent of apoptosis in the sample is contemplated. For example, normal-appearing mucosa from the distal colon and/or rectum may be obtained from individuals undergoing screening procedures for colorectal cancer. The tissue is subjected to a method that assesses apoptosis, for example, by the extent of broken DNA ends in the nuclei of the cells in the specimen. The extent of apoptosis is expressed as a numerical ratio and indicates the possibility that an individual patient has a premalignant or malignant lesion in his or her colon or the risk for the development of a colorectal neoplasm in the future. Furthermore, the method has utility in determining whether a patient with, or at risk of developing, colorectal neoplasia is responding to prevention or intervention therapy.